Source comparison
Thymosin Alpha-1 Results After 1 Month: Clinical vs Laboratory Findings
CD4+ T-cell count +15–25% (150–250 cells/µL in immunocompromised patients) Laboratory marker only. Not necessarily symptomatic Early adaptive immune reconstitution; full effect requires 8–12 weeks CD8+ T-cell count +18–30% Laboratory marker only Cytotoxic T-ce
This comparison does not assign a generated winner or score.
- CD4+ T-cell count
- +15–25% (150–250 cells/µL in immunocompromised patients)
- Laboratory marker only. Not necessarily symptomatic
- Early adaptive immune reconstitution; full effect requires 8–12 weeks
- CD8+ T-cell count
- +18–30%
- Laboratory marker only
- Cytotoxic T-cell expansion; correlates with improved viral clearance by week 8–10
- IL-2 serum levels
- +30–50%
- Reflects Th1 activation
- Functional marker of immune readiness; symptom improvement lags behind
- Viral load (HBV, HCV)
- −0.2 to −0.5 log10 copies/mL
- Not clinically significant at 4 weeks
- Meaningful suppression (≥1 log10 reduction) requires 8+ weeks
- NK cell cytotoxicity
- +20–35% in vitro
- Laboratory assay. Indirect clinical relevance
- Improved innate surveillance; clinical impact unclear without infection challenge
- Symptom scores (fatigue, malaise)
- Variable; 30–40% report subjective improvement
- Likely placebo-confounded at 4 weeks
- Sustained improvement requires 6–8 weeks of dosing